Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Neuronetics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
34.2
40.4
52.8
62.7
49.2
55.3
65.2
71.3
74.9
149
Cost of revenue
6.62
9.63
12.4
15.4
11.6
11.7
15.5
19.6
20.7
76.8
Gross profit
27.6
30.8
40.3
47.3
37.7
43.7
49.7
51.7
54.2
72.3
Research and development
8.22
7.94
8.23
13.7
9.2
7.92
9.34
9.52
12.8
6.58
Selling and marketing
21.8
27.9
38.3
43
32.6
37.7
50
47.3
45.6
47.5
General and administrative
6.93
8.57
13.7
17.5
18.2
25.6
25.5
25.4
30.3
49.7
Operating expenses
36.9
44.4
60.2
74.2
60
71.2
84.8
82.3
88.7
104
Operating income
-9.34
-13.6
-19.8
-26.9
-22.3
-27.6
-35.1
-30.6
-34.6
-31.4
Interest expense
1.84
2.81
3.69
3.69
4.52
4.02
4.25
5.42
7.29
8.42
Other non-operating income
-0.06
0.36
-0.58
1.57
0.3
0.39
2.2
5.79
2.55
0.72
Pre-tax income
-11.2
-16.1
-24.1
-29
Net income to minority interests
-0.02
-0.14
Net income
-11.2
-16.1
-24.1
-29
-27.5
-31.2
-37.2
-30.2
-43.7
-39
EBITDA
-8.66
-13
-19
-25.9
-21.4
-26.5
-33.5
-28.5
-32.5
-28
EPS, basic
-76.95
-86.34
-2.69
-1.58
-1.46
-1.22
-1.38
-1.05
-1.38
-0.59
EPS, diluted
-76.95
-86.34
-2.69
-1.58
-1.46
-1.22
-1.38
-1.05
-1.38
-0.59
Shares, basic (weighted)
0.15
0.19
8.95
18.4
18.8
25.5
26.9
28.7
31.7
66
Shares, diluted (weighted)
0.15
0.19
8.95
18.4
18.8
25.5
26.9
28.7
31.7
66
Balance sheet
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
17
29.1
105
75.7
49
94.1
70.3
59.7
18.5
28.1
Receivables
4.27
5.62
6.57
7.17
7.71
13.6
15.8
23.4
16.5
Inventory
2.47
2.43
2.78
3.72
6.56
8.9
8.09
4.25
4.33
Other current assets
1.12
1.84
1.83
2.19
3.09
2.17
4.77
6.85
2.92
Total current assets
37
114
88.5
65
115
98.8
93.8
58.1
61.6
Property, plant and equipment
1.36
1.38
1.11
0.73
1.22
1.99
2.01
6.24
4.47
Lease right-of-use assets
3.8
3.42
3.88
3.33
2.77
27.1
23.6
Goodwill
18.6
23.6
Intangible assets
19.6
18.1
Other non-current assets
0.57
1.17
1.31
1.87
2.22
3.65
4.43
1.92
1.98
Total assets
38.9
117
100
78.7
141
117
116
141
142
Accounts payable
2.51
3.76
4.63
3.75
4.3
2.43
4.75
11.1
10.7
Accrued liabilities
7.51
7.55
9.03
7.32
8.23
14.8
12.6
12.8
12.3
Deferred revenue
1.97
2.26
2.23
2.02
2.5
1.98
1.62
0.97
0.75
Short-term debt
0
11.3
13.1
Total current liabilities
12
13.6
27.7
13.7
15.7
33.2
19.8
31.3
30.5
Long-term debt
29.6
30.4
19.9
34.6
35.3
22.8
59.3
55.2
65.8
Lease liabilities
2.62
3.12
3.54
2.97
2.35
22.7
18.9
Total liabilities
44.5
46
52.3
53.2
56
59.8
81.6
109
115
Total debt
29.6
30.4
31.1
34.6
35.3
36
59.3
55.2
65.8
Paid-in capital
4.29
292
298
303
394
403
410
447
480
Retained earnings
-197
-221
-250
-278
-309
-346
-376
-420
-459
Shareholders' equity
-177
-193
71
47.9
25.5
85.2
57.1
34.2
27.7
22.4
Minority interests
4.09
3.86
Total equity
-177
-193
71
47.9
25.5
85.2
57.1
34.2
31.8
26.2
Total liabilities and equity
38.9
117
100
78.7
141
117
116
141
142
Shares outstanding
0.23
17.7
18.6
19.1
26.4
27.3
29.1
55.7
69
Cash flow statement
FY2016
FY2018
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-11.2
-16.1
-24.1
-29
-27.5
-31.2
-37.2
-30.2
-43.7
-39.1
Depreciation and amortization
0.67
0.6
0.88
1.07
0.94
1.06
1.65
2.01
2.07
3.47
Stock-based compensation
0.16
0.5
1.74
3.43
4.4
7.87
8.75
7.32
5.6
6.85
Deferred income tax
0
0
0
0
0
0
0
0
0
0
Change in receivables
-0.12
-0.69
-1.35
-0.95
-0.6
-3.82
-6.66
-8.83
-3.73
3.54
Change in inventory
-0.65
-1.07
-0.44
-0.31
-0.95
-3.44
-2.59
-1.1
3.15
-0.4
Change in payables
0.73
0.79
0.61
0.3
-1.09
0.28
-1.97
2.03
-1.99
-1.75
Cash from operations
-8.54
-11.1
-20.6
-30.5
-28.4
-28
-30.7
-32
-31
-20.4
Capital expenditures
-0.32
-0.59
-1.01
-0.81
-0.73
-2.35
-3.27
-2.37
-1.47
-0.8
Acquisitions
-2.55
Cash from investing
-0.32
-0.59
-1.01
-0.81
-0.73
-9.84
6.73
-1.32
-2.41
-0.8
Debt issued
41.4
25
57.5
10
Debt repaid
-38.9
-1.2
-60
Stock issued
0.07
0.04
0.5
2.42
0.69
81
0.3
0
0
0.01
Cash from financing
4.9
23.8
97
2.42
2.37
83
0.21
22.7
-6.81
35.9
Net change in cash
-3.97
12.1
75.4
-28.9
-26.8
45.2
-23.8
-10.7
-40.2
14.7
Free cash flow
-8.87
-11.7
-21.6
-31.3
-29.1
-30.3
-34
-34.4
-32.5
-21.2
Interest paid
1.41
2.04
2.79
2.95
3.89
3.3
3.54
4.79
6.51
7.59
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $2.74 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Gross margin
49.1%
Gross profit / revenue.
Operating margin
-14.7%
Operating income / revenue.
EBITDA margin
-13.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Net margin
-19.6%
Net income / revenue.
FCF margin
-7.3%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-6.7%
Cash from operations / revenue.
Return on equity (ROE)
-170.5%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-23.1%
Net income / average total assets.
Return on invested capital (ROIC)
-30.0%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
R&D / revenue
3.8%
Research and development expense / revenue.
Stock-based pay / revenue
3.8%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
0.6%
Capital expenditures / revenue.
D&A / revenue
1.6%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
99.2%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
31.8%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y
24.8%
Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y
33.5%
Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y
13.3%
Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y
13.9%
Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y
-19.2%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-26.8%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-2.6%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
0.5%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
6.6%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
12.5%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
107.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
34.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
28.5%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
1.88x
Current assets / current liabilities.
Quick ratio
1.24x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
0.68x
(Cash + short-term investments) / current liabilities.
Debt / equity
3.45x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
46.8%
Total debt / total assets.
Liabilities / assets
83.5%
Total liabilities / total assets.
Net debt
$42.3M
Total debt - cash - short-term investments. Negative means more cash than debt.
Days inventory + days sales outstanding - days payables.
Per share
Metric
Value
How it is calculated
EPS, diluted
-$0.42
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$2.12
Revenue / diluted weighted shares.
FCF per share
-$0.15
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.14
Cash from operations / diluted weighted shares.
Book value per share
$0.23
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
1.35x
Market cap / revenue.
P/B
11.7x
Market cap / shareholders' equity. Only when equity is positive.
EV/Sales
1.62x
Enterprise value / revenue.
FCF yield
-5.4%
Free cash flow / market cap.
Earnings yield
-14.6%
Net income / market cap (the inverse of P/E).
What was Neuronetics, Inc.'s revenue in fiscal 2025?
Neuronetics, Inc. reported revenue of $149.2M for fiscal 2025, 99.2% higher than the year before.
Was Neuronetics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $39.0M.
How much free cash flow did Neuronetics, Inc. generate in fiscal 2025?
Cash from operations of $20.4M minus capital expenditures of $801.0K left free cash flow of -$21.2M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.